Top Novartis Heart Drug to go off Patent

The pharma retail market for cardiology, one of the fastest expanding therapeutic areas after diabetes, is about to see considerable activity as a blockbuster medicine is about to lose its patent protection. With the blockbuster cardiology medicine from Swiss company Novartis losing its patent protection in January, prominent businesses like Natco, Cipla, Torrent, Lupin, Sun Pharma, and USV are preparing plans to join the Rs 24,000-crore market to get a piece of the opportunity.

With over 50 businesses introducing generic copies of Swiss firm Novartis's heart failuremedicine, Vymada (Sacubitril and Valsartan), for a fraction of the innovator's price, industry analysts anticipate fierce competition in the heart failure market. As a result, those who have heart issues might anticipate significant healthcare cost reductions. The drug's compound annual growth rate is close to 40%. (CAGR). It is one of the compounds in the field of cardiology with the quickest growth. Patients with heart failure and a low ejection fraction are advised to use the combination of Sacubitril and Valsartan, which is presently covered by a Novartis patent. The heart failure medication Entresto, with an estimated $4 billion in yearly sales globally, is marketed by the Swiss company.

Affordable versions of the popular medication are anticipated to reach retail pharmacies in January, cutting the cost of the treatment in half. When less expensive versions of the popular diabetes medication Januvia (Sitagliptin) from US Merck joined the market in July, cutting patients' costs by almost a third, a similar trend was seen in another chronic therapy.

In the entire world, cardiovascular diseases (CVDs) are the main cause of mortality. According to the World Health Organization, almost 35% of all deaths in India would be attributable to CVDs by 2030, up from 25% in 2016. Dr. Reddy's, JB Chemicals, Mankind, and other businesses are currently promoting it under their own names in addition to Novartis' Vymada. In February 2017, the Swiss company introduced its brand in India and granted in-licensing rights to Cipla and Lupin.

Heart failure is a chronic, progressive illness marked by a decline in quality of life and functional status. Worldwide, an estimated 23 million people struggle with heart failure. About 1% of the population in India is thought to be affected.

Contact Us:

BlueWeave Research Blog

Phone No: +1 866 658 6826

Email: info@blueweaveconsulting.com